Condition (MeSH)
Impotence, Vasculogenic
ClinicalTrials.gov lists 2 trials for Impotence, Vasculogenic or a narrower condition beneath it. Central Clinical Hospital w/Outpatient Health Center of Business Administration for the President of Russian Federation has the most among industry and government lead sponsors, with 1.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase
2 of the 2 trials are tagged with Impotence, Vasculogenic itself; the rest are tagged with a narrower condition beneath it.
When did Impotence, Vasculogenic trials start? (1)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
| Year | Trials started |
|---|---|
| 2015 | 2 |
No forecast is made for this condition: it averages 0.0 trial starts a year over the five years to September, under the 5 a year the method needs.
Recruitment duration, a model prediction: none of the 2 trials evaluated at the 2026-10-09 snapshot is predicted and still running. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Impotence, Vasculogenic trials in? (2)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 1/2 | 1 |
| Phase 2/3 | 1 |
How many Impotence, Vasculogenic trials are recruiting? (2)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Completed | 1 |
| Unknown status | 1 |
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Impotence, Vasculogenic trials? (1)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| Central Clinical Hospital w/Outpatient Health Center of Business Administration for the President of Russian Federation | 1 |
Which publications cover Impotence, Vasculogenic? (35)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| Endovascular Therapy for Erectile Dysfunction-Who Benefits Most? Insights From a Single-Center Experience. | Journal of endovascular therapy : an official journal of the International Society of Endovascular Specialists | 2019 | Yes |
| Penile doppler ultrasound predicts cardiovascular events in men with erectile dysfunction. | Andrology | 2019 | Yes |
| Endovascular Therapy for Vasculogenic Erectile Dysfunction: A Systematic Review and Meta-Analysis of Arterial and Venous Therapies. | Journal of vascular and interventional radiology : JVIR | 2019 | Yes |
| Low-Intensity Shockwave Therapy Improves Hemodynamic Parameters in Patients With Vasculogenic Erectile Dysfunction: A Triplex Ultrasonography-Based Sham-Controlled Trial. | The journal of sexual medicine | 2017 | Yes |
| Vessel-sparing Radiotherapy for Localized Prostate Cancer to Preserve Erectile Function: A Single-arm Phase 2 Trial. | European urology | 2017 | Yes |
Showing 5 of 35 publications.
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: serious adverse events in this condition's trials, prevalence, rare-disease identity, and sub-conditions in mesh.
Not computed for conditions with fewer than 10 trials: drugs tested.